Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2023)

Candel Therapeutics' Change in Accured Expenses history spans 4 years, with the latest figure at $946000.0 for Q4 2023.

  • For Q4 2023, Change in Accured Expenses rose 117.47% year-over-year to $946000.0; the TTM value through Dec 2023 reached -$301000.0, down 123.79%, while the annual FY2024 figure was $757000.0, 351.5% up from the prior year.
  • Change in Accured Expenses for Q4 2023 was $946000.0 at Candel Therapeutics, up from -$85000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.4 million in Q4 2020 and bottomed at -$1.8 million in Q1 2023.
  • The 4-year median for Change in Accured Expenses is $310500.0 (2022), against an average of $198714.3.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 510.61% in 2021 before it tumbled 2088.89% in 2023.
  • A 4-year view of Change in Accured Expenses shows it stood at $1.4 million in 2020, then plummeted by 48.24% to $719000.0 in 2021, then crashed by 39.5% to $435000.0 in 2022, then soared by 117.47% to $946000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Change in Accured Expenses are $946000.0 (Q4 2023), -$85000.0 (Q3 2023), and $628000.0 (Q2 2023).